Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - mišićna atrofija, kralješnica - ostali lijekovi za poremećaje mišićno-koštanog sustava - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresivi - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imuni serumi i homologna, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

roche d.o.o.roche ltd. - risdiplam - prašak za oralnu otopinu - 0,75 mg/1 ml - 1 bočica sa 2 g praška za oralnu otopinu sadrži 60 mg risdiplama (1 ml rekonstituirane otopine sadrži 0,75 mg risdiplama)

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - kolitis, ulcerativni - imunosupresivi - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - levobupivakainklorid - otopina za injekciju/infuziju - 5 mg/ml - urbroj: 1 ml otopine sadrži 5 mg levobupivakaina u obliku levobupivakainklorida

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - ropivakainklorid - otopina za infuziju - urbroj: 1 ml otopine sadrži 2 mg ropivakainklorida